Effect of Vitamin d and Omega 3 on Osteocalcin

Applied Science Private University120 enrolled

Overview

Assessing the combined effect of omega-3 fatty acid and vitamin D 3 on plasma osteocalcin levels

The data about effect of vitamin D3 (VD3) and omega-3 fatty acids(omega-3FA) on plasma levels of osteocalcin (OCN) are scarce and conflicting and nothing is published in the literature about the effect of the combination of VD3 and omega-3FA on the OCN levels. This study was conducted to investigate effect of VD3 and omega-3FA alone and with each other on PLASMA OCN levels in females and males with vitamin D deficiency (VDD). This randomized, controlled clinical trial was designed to test effects of 50,000 IU VD3 weekly and 300 mg omega-3FA daily for eight weeks,separately and with each other, on the plasma levels of OCN and 25-hydroxy vitamin D (25OHD). This study was conducted during winter in 86 healthy Jordanian females and males with VDD with a mean age of (40± 10) years. Fasting serum levels for 25OHD,OCN, PTH (parathyroid hormone),calcium, phosphate, ALT (alanine aminotransferase), and urea were assessed at baseline and the end of the trial .

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

120

Conditions

Vitamin D Deficiency

Interventions

vitamin D3DIETARY_SUPPLEMENT

50,000 IU VD3 / week for 8 weeks

omega-3 fatty acidDIETARY_SUPPLEMENT

300 mg of omega 3-FA once daily for 8 weeks

vitamin D3 and omega-3 fatty acidDIETARY_SUPPLEMENT

50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks

Eligibility

Sex: ALLMin age: 22 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Medical diagnosis of vitamin D deficiency (VD \< 30 ng / ml). Exclusion Criteria: * People who previously diagnosed with any chronic disease such as kidney diseases were excluded from the study due to the effect of prolonged administration of VD3 on kidney stones formation. * People with bone disorders also excluded.

Locations (1)

Applied Science University

Amman, Jordan

Outcomes

Primary Outcomes

vitamin d3 levels

Plasma levels of 25-hydroxyvitamin D

Time frame: 8 weeks

osteocalcin levels

plasma osteocalcin levels

Time frame: 8 weeks

Secondary Outcomes

PTH

Plasma concentrations of PTH

Time frame: 8 weeks

calcium

plasma Ca levels

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.